Deals
J&J Unit to Sell Sylvant Rights to U.K. Drugmaker Eusa Pharma
- Acquisition would bolster Eusa’s focus on rare diseases
- Eusa Pharma agrees to pay J&J’s Janssen $115 million in cash
Photographer: Scott Eells/Bloomberg
This article is for subscribers only.
A unit of U.S. health-care giant Johnson & Johnson has agreed to sell global rights to a treatment for a rare blood disorder to Britain’s Eusa Pharma.
Eusa Pharma is buying the rights to the drug Sylvant from Janssen Sciences Ireland UC for $115 million in cash, the Hemel Hempstead, England-based company said Wednesday, confirming a Bloomberg report. The transaction is pending regulatory approval.